Parkinson's disease

The FDA approved Medtronic’s adaptive deep brain stimulation system, which delivers electrical stimulation in real time based on the brain’s state.

From an executive order to lower drug prices to GLP-1 drug comparisons and a link between Parkinson’s disease and golf courses, it was a busy industry news week.

The enzyme PGK1 sets the rate of cellular energy production and may be an ideal drug target when Parkinson’s disease neurons struggle to fuel themselves.

Scores of neurons are already dead by the time Parkinson’s disease is usually diagnosed. Scientists aim to identify patients earlier and intervene before it’s too late.

Targeting α-synuclein mRNA before it had a chance to aggregate reduced its protein levels in cultured dopaminergic neurons and may protect neurons.

Scientists coupled mass spectrometry imaging with spatial transcriptomics in a single tissue, allowing for new discoveries in rare samples.

Slight modifications to glycoproteins reveal critical insights into disease onset, state, and progression, making them a wellspring for biomarker discovery. 

By measuring neural oscillations in the brain, Isabelle Buard studies the effect of music therapy on improving fine motor movements in neurological disorders.

This year’s Breakthrough Prizes honor advances in CAR T cancer therapies, cystic fibrosis, and Parkinson’s disease.

A new form of brain stimulation treatment that responds to a patient’s brain activity could be life changing for people with neurological and psychiatric disorders.